Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)

Spinogenix Announces World Health Organization Approval of ‘tazbentetol’ as International Non-Proprietary Name for SPG302

Spinogenix Presents Topline Phase 2a Clinical Trial Results for SPG302, a First-in-Class ALS Treatment

Spinogenix to Present Complete Phase 2a Clinical Trial Results for SPG601, a First-in-Class Fragile X Syndrome Treatment, at AACAP Conference

Spinogenix Announces Publication of Preclinical Study Demonstrating Neuroprotective Effects of SPG302 in a Model of Glaucoma

Spinogenix Announces Positive Type C Meeting with the FDA for SPG601 in Patients with Fragile X Syndrome (FXS)

Spinogenix Announces Positive First Cohort Results from Phase 2a Trial Evaluating SPG302 for Alzheimer’s Disease

European Medicines Agency Grants Orphan Drug Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome (FXS)

Spinogenix Announces Full Enrollment in its Phase 2 Trial Evaluating SPG302 as a First-in-Class Synaptic Regenerative Therapy for Alzheimer’s Disease

Spinogenix’s SPG302, the First Synaptic Regenerative Therapy to Treat ALS, Granted Orphan Drug Designation by the European Medicines Agency

Spinogenix Announces FDA-Authorized Expanded Access Programfor SPG302, the First Synaptic Regenerative Therapy to Treat ALS

Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for Schizophrenia

Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity

FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism

Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors

Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board

Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia

Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X syndrome

Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease

Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)